Clinical Trial Update: Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial update on secukinumab in active psoriatic arthritis showing efficacy at 24 weeks with long-term safety, tolerability, and efficacy data up to 5 ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2020-05-13